Saturday 17 October 2026 Export TCRT’s income statement to Excel — free account

Alaunos Therapeutics, Inc.

Alaunos Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5,000.00, down 50.0% from fiscal 2024. In the quarter to June 2026, revenue grew 200.0%, EPS grew 34.9% and free cash flow grew 57.2%, each against the same quarter a year earlier.

2.63 0.45 +20.64%

Follow TCRT

Alert me

Market cap: $6.4M
P/E: 0.0×
Fwd P/E: −2.1×
Dividend yield: —
F-score: 2/9
Altman Z: −436.02
Beneish M: −4.88
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 4.19%

Capital & Financial Ratios $m

Market Cap 6.38

Revenue 0.01

Net Income (4.01)

Free Cash Flow (2.73)

Net Debt (0.12)

Current Ratio 0.77

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (2.13)

P/S ratio 456.87

P/B ratio 9.81

Past 5Y EPS Growth —

This Y EPS Growth 11.76%

Next Y EPS Growth 73.33%

Next Y revenue growth (100.00%)

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 93.03%

10-year low 10-year high

P/B against its own 10 years 90.16%

10-year low 10-year high

EV/Sales against its own 10 years 87.65%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	6	1	1	0
Receivables	0	0	0	—
Inventory	—	—	—	—
Other	—	—	—	—
	8	3	2	1

	2023	2024	2025	Q'26
Payables	1	1	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	2	1	1	1

Compound Annual Growth %

	10y	5y	3y
Sales	—	(49.08%)	(88.04%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(30.95%)	(55.54%)	(61.78%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	0	—	—	0	0
’24	0	0	—	0	0
’23	—	0	—	0	0
’22	—	—	3	0	3
’21	—	—	0	—	0
’18	0	—	—	—	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	0	—	—	—
’25	(1)	(1)	(1)	(1)	(3)
’24	(2)	(2)	(1)	(1)	(5)
’23	(9)	(7)	(6)	(7)	(30)
’22	(8)	(8)	(6)	(7)	(29)
’21	(15)	(21)	(10)	(15)	(61)
’20	(10)	(14)	(16)	(17)	(57)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	0	—	—	—
’25	(1)	(1)	(1)	(1)	(3)
’24	(2)	(2)	(1)	(1)	(5)
’23	(9)	(7)	(6)	(6)	(29)
’22	(8)	(8)	(6)	(7)	(29)
’21	(16)	(23)	(10)	(15)	(65)
’20	(10)	(17)	(18)	(21)	(67)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.59)	(0.41)	—	—	—
’25	(0.67)	(0.63)	(0.55)	(0.36)	(2.20)
’24	(1.10)	(0.71)	(0.70)	(0.46)	(2.92)
’23	(6.00)	(6.00)	(6.00)	(4.89)	(22.00)
’22	(7.50)	(7.50)	(6.00)	(6.00)	(25.49)
’21	(14.99)	(16.49)	(16.49)	(7.50)	(55.47)
’20	(13.49)	(13.49)	(14.99)	(16.49)	(56.97)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	667.50	585.00	234.00	271.50	270.00	160.50	61.50	6.00	1.63	1.31	Analyst estimates 2026–2028 Powerpack
	High	1,461.00	1,182.00	787.50	1,087.50	766.50	892.50	601.50	129.00	33.00	6.20
People
People	Employees	36	46	48	73	106	41	34	1	1	1
	Revenue/emp, $m	0.19	0.14	0.00	0.00	0.00	0.01	0.09	0.01	0.01	0.01
Income, $m
Income, $m	Revenue	7	6	0	—	—	0	3	0	0	0
	Gross margin, %	100.00	100.00	100.00	0.00	0.00	100.00	100.00	100.00	100.00	100.00
	EBT	(165)	(54)	(53)	(118)	(80)	(79)	(38)	(35)	(5)	(4)
	EBT margin, %	(2,409.23)	(850.26)	(36,381.51)	0.00	0.00	(19,786.68)	(1,291.24)	(702,800.00)	(46,790.00)	(83,520.00)
	Net income	(165)	(54)	(53)	(118)	(80)	(79)	(38)	(35)	(5)	(4)
	Depreciation	0	0	1	1	1	3	4	4	0	0
Per share, $
Per share, $	Revenue	7.89	6.99	0.15	0.00	0.00	0.28	2.02	0.00	0.01	0.00
	Earnings	(197.90)	(79.46)	(55.49)	(104.95)	(56.97)	(55.47)	(25.49)	(22.00)	(2.92)	(2.20)
	Cash flow	(67.06)	(59.85)	(51.67)	(36.47)	(40.77)	(42.98)	(20.19)	(18.84)	(3.10)	(1.47)
	Capex	(0.63)	(0.81)	(0.48)	(0.25)	(6.99)	(2.32)	(0.13)	0.84	0.00	(0.05)
	Free cash flow	(67.70)	(60.66)	(52.15)	(36.72)	(47.77)	(45.31)	(20.33)	(18.00)	(3.10)	(1.52)
	Book value	(88.88)	(105.98)	89.39	84.82	88.67	40.60	26.64	3.94	1.29	1.11
	Shares, m	1	1	1	1	1	1	1	2	2	2
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	—	—	0.00	0.00	0.00	0.00	0.00
	P/S	104.01	95.21	54.37	—	—	62.53	39.47	7.38	278.04	449.52
	P/B	0.00	0.00	3.14	—	—	4.03	3.55	3.42	1.48	2.92
	EV/Sales	92.19	84.11	41.87	—	—	48.64	30.30	10.59	1,584.32	1,454.88
	EV/FCF	(10.74)	(9.70)	(4.14)	—	—	(2.81)	(3.57)	(1.08)	(4.81)	(13.92)
Cash, $m
Cash, $m	Operating cash flow	(58)	(55)	(49)	(41)	(57)	(61)	(29)	(30)	(5)	(3)
	Capex	(1)	(1)	0	0	(10)	(3)	0	1	—	0
	Free cash flow	(59)	(55)	(50)	(41)	(67)	(65)	(29)	(29)	(5)	(3)
Balance, $m
Balance, $m	Working capital	89	70	75	93	112	63	30	6	2	1
	Total debt	—	—	—	2	5	24	17	—	—	—
	Net debt	(81)	(71)	(62)	(77)	(110)	(52)	(36)	(6)	(1)	(1)
	Shareholders’ equity	(77)	(97)	86	95	124	58	39	6	2	2
Returns, %
Returns, %	ROA	(132.59)	(69.13)	136.80	(115.39)	(62.61)	(65.30)	(47.22)	(96.01)	(84.93)	(145.99)
	ROIC	0.00	0.00	(141.35)	(205.22)	(365.89)	(791.83)	(944.09)	(8,741.58)	(309.41)	(343.83)
	ROE	(3,423.41)	84.16	(2,441.67)	(130.47)	(73.04)	(86.52)	(78.11)	(156.66)	(111.80)	(198.10)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SYBX Synlogic, Inc.	$6.7M	— (loss-making)	— (loss-making)	−95.40% (below 0%: shrinking)	n/m	−277.87% (below 0%: shrinking)	100.00%	0.00%	Compare
FBLG FibroBiologics Inc.	$6.7M	— (loss-making)	—	—	n/m	+21.59% (above 0%: growing)	—	0.00%	Compare
ACXP Acurx Pharmaceuticals, Inc.	$6.5M	— (loss-making)	—	—	n/m	−2.36% (below 0%: shrinking)	—	0.00%	Compare
TCRT Alaunos Therapeutics, Inc.	$6.4M	— (loss-making)	— (loss-making)	+200.00% (above 0%: growing)	n/m	+57.20% (above 0%: growing)	100.00%	0.00%
EVGN Evogene Ltd.	$6.3M	— (loss-making)	— (loss-making)	−35.02% (below 0%: shrinking)	n/m	+17.72% (above 0%: growing)	40.63%	(738.62%)	Compare
LEXX Lexaria Bioscience Corp.	$6.3M	— (loss-making)	— (loss-making)	−89.12% (below 0%: shrinking)	n/m	+53.90% (above 0%: growing)	100.00%	0.00%	Compare
ENVB Enveric Biosciences, Inc.	$6.2M	— (loss-making)	— (loss-making)	−7.28% (below 0%: shrinking)	n/m	−29.34% (below 0%: shrinking)	0.00%	0.00%	Compare
TRAW Traws Pharma, Inc.	$6.2M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−25.51% (below 0%: shrinking)	0.00%	0.00%	Compare
ALZN Alzamend Neuro, Inc.	$6.2M	— (loss-making)	—	—	n/m	+51.82% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$6.3M	—	—	−89.12%	—	+7.68%	20.32%	0.00%

All 614 Biotechnology stocks →